Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Short-term Investments (2020 - 2025)

10x Genomics' Short-term Investments history spans 6 years, with the latest figure at $49.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments changed 0.22% year-over-year to $49.4 million; the TTM value through Dec 2025 reached $49.4 million, changed 0.22%, while the annual FY2025 figure was $49.4 million, 0.22% changed from the prior year.
  • Short-term Investments for Q4 2025 was $49.4 million at 10x Genomics, roughly flat from $49.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $225.5 million in Q2 2022 and bottomed at $27000.0 in Q1 2022.
  • The 5-year median for Short-term Investments is $17.1 million (2021), against an average of $31.3 million.
  • The largest annual shift saw Short-term Investments plummeted 99.95% in 2021 before it soared 18319.7% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $28000.0 in 2021, then soared by 9303.57% to $2.6 million in 2022, then soared by 1017.01% to $29.4 million in 2023, then skyrocketed by 67.74% to $49.3 million in 2024, then increased by 0.22% to $49.4 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Short-term Investments are $49.4 million (Q4 2025), $49.6 million (Q3 2025), and $49.5 million (Q2 2025).